{
  "docId": "019dd923-605c-759f-b6b3-8249779ff12a",
  "docSlug": "bi-b9ee0ec18d1bb159",
  "documentTitle": "Pitch deck: SparingVision raises $75 million for CRISPR eye treatments",
  "authorId": "Pitchdecks",
  "authorName": "SparingVision",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.779,
  "pageNumber": 16,
  "pageCount": 20,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to explain the 'why' behind the partnership, followed by a summary box on the right.",
  "elementsJson": [
    "bullet_list",
    "callout_box",
    "icon_grid"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-605c-759f-b6b3-8249779ff12a/16",
  "deckHref": "/decks/019dd923-605c-759f-b6b3-8249779ff12a",
  "deckJsonHref": "/decks/019dd923-605c-759f-b6b3-8249779ff12a.json",
  "deckAnchorHref": "/decks/019dd923-605c-759f-b6b3-8249779ff12a#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.75,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Goal to disrupt the ophthalmology field and address areas of significant unmet need. Includes R&D partnership to identify novel self-inactivating AAV vectors and LNP-based approaches to enter the retina",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b3f9ec2-3b5e-41fc-aee3-8132c14c6eb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Goal to disrupt the ophthalmology field and address areas of significant unmet need.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-c5b1-7611-ab40-4fc6fc290c6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.78,
        "y": 0.2
      },
      "kind": "image",
      "text": "SparingVision Intellia logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "275a20d4-7bce-4c20-998d-72ab26d287d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.26,
        "y": 0.35
      },
      "kind": "list",
      "text": "Compelling potential of CRISPR/Cas9 in the eye: Directly accessible, small, stable, immune-privileged, numerous mutations and models; Safety profile of sub-retinal, AAV approach already confirmed in the clinic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51e3d678-f545-4227-9393-aac5dced2b29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.49,
        "y": 0.35
      },
      "kind": "list",
      "text": "The perfect strategic partner: Leading genome editing platform; First with in human (in vivo) proof of concept; Full spectrum strategy with shared focus on diseases with high unmet need; Proprietary LNP delivery system enabling multiple editing strategies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aeabcf8b-5a02-4bf9-8cb1-b61f0757403e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "list",
      "text": "Complementary to gene therapy: i.e. indications where the gene is too large or the mutation cannot be addressed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa0949eb-c6ac-4704-b474-b619f0adca7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Partnership agreement with Intellia",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae691e49-5779-4525-8448-7b81492cecc5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}